Chalcogen Bonded Directly To The Five-membered Hetero Ring By Nonionic Bonding Patents (Class 514/424)
-
Publication number: 20100240700Abstract: Methods, compositions, and uses for pre-treating patients who are susceptible to ischemia, including stroke, with nitroxides, in order to prevent or ameliorate the effects of stroke or other ischemic disease.Type: ApplicationFiled: June 3, 2010Publication date: September 23, 2010Applicant: MITOS PHARMACEUTICALS, INC.Inventor: Kameron W. Maxwell
-
Patent number: 7799823Abstract: The present invention is directed to a new class of benzonitriles and to their use as androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease excess sebum secretions and to stimulate hair growth.Type: GrantFiled: November 7, 2006Date of Patent: September 21, 2010Assignee: Warner-Lambert Company LLCInventors: Stephen Douglas Barrett, Victor Fedij, Lain-Yen Hu, Donna M Iula, Bruce A Lefker, Raj Kumar Raheja, Karen Sexton, Jennifer Ann Van Camp
-
Publication number: 20100234411Abstract: The present invention relates to novel pharmaceutical compositions based on telmisartan 1 and anticholinergics 2 processes for preparing them and their use for the treatment of respiratory diseases.Type: ApplicationFiled: July 14, 2008Publication date: September 16, 2010Applicant: BOEHRINGER INGELHEIM INTERMATIONAL GMBHInventors: Yunhai Cui, Wolfgang Wienen, Michael P. Pieper
-
Publication number: 20100234365Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).Type: ApplicationFiled: December 12, 2007Publication date: September 16, 2010Applicant: IRM LLCInventors: Hong Liu, Xiaohui He, Dean Phillips, Xuefeng Zhu, Kunyong Yang, Thomas Lau, Baogen Wu, Yongping Xie, Truc Ngoc Nguyen, Xing Wang
-
Publication number: 20100233249Abstract: The present invention concerns the use of compositions and methods of regulating or evaluating fertility in an animal, in particular a mammal. In various embodiments of the invention, methods of contraception include inhibiting proteasome activity of a gamete, in particular spermatozoon. Proteasomal activity may be inhibited in vitro or in vivo. Inhibitors of the proteasome pathway include, but are not limited to small molecules, peptides, polypeptides (e.g., antibodies and the like) and affinity reagents that bind various components of the proteasome pathway (e.g., aptamers, etc.). In some embodiments, the activity of the proteasome pathway or the activity of a component in the proteasome pathway is inhibited by antibodies that bind and inhibit one or more components of the proteasome pathway.Type: ApplicationFiled: December 29, 2009Publication date: September 16, 2010Inventors: Peter Sutovsky, Billy N. Day, Tod C. McCauley, Miriam Sutovsky
-
Publication number: 20100234349Abstract: This invention relates to novel pharmaceutical compositions comprising therapeutically effective combination of a positive allosteric modulator of nicotine receptors; and a cognitive enhancer selected from the group consisting of a nicotine acetylcholine receptor agonist, an acetylcholine esterase inhibitor, a positive AMPA receptor modulator, an antipsychotic drug, an antidepressant drug and an anti Parkinson drug. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for combating cognitive disorders.Type: ApplicationFiled: September 4, 2007Publication date: September 16, 2010Inventors: Gunnar M. Olsen, Dan Peters, Bjarne H. Dahl, Jeppe Kejser Christensen, Steven Charles Loechel, Daniel B. Timmermann
-
Publication number: 20100226993Abstract: A composition for regenerative treatment of cartilage disease, which comprises a PDE4 inhibitor as an active ingredient, specifically a composition comprising a PDE4 inhibitor and a biocompatible and biodegradable polymer is provided, which composition, when formulated into a form suited to administer locally to affected cartilage region, such as microsphere preparation, can provide a pharmaceutical composition showing an excellent effect in regenerative treatment of cartilage.Type: ApplicationFiled: May 18, 2010Publication date: September 9, 2010Inventors: Masaharu TAKIGAWA, Naoki Sakurai, Toshiki Takagi, Noriyuki Yanaka, Yuji Horikiri, Takashi Tamura
-
Publication number: 20100227853Abstract: Recombinant fission yeast cells and methods of using them are described, which provide for identification of chemical and biological inhibitors or activators of a target exogenous phosphodiesterase (PDE). The invention provides, in some aspects, compounds that inhibit cAMP PDE activity and compositions that include such compounds. The invention, in part, also includes methods of using cAMP PDE-inhibiting compounds in the treatment of cAMP PDE-associated diseases and/or disorders.Type: ApplicationFiled: April 17, 2009Publication date: September 9, 2010Applicant: Trustees of Boston CollegeInventors: Charles S. Hoffman, Frank Douglas Ivey, Arlene Wyman Petri
-
Publication number: 20100222326Abstract: The present invention relates to new compounds, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.Type: ApplicationFiled: April 24, 2008Publication date: September 2, 2010Applicant: UCB PHARMA, S.A.Inventors: Benoit Kenda, Laurent Turet, Yannick Quesnel, Philippe Michel, Ali Ates
-
Patent number: 7786150Abstract: Disclosed herein is a compound having a structure or a pharmaceutically acceptable salt, or a prodrug thereof. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.Type: GrantFiled: May 14, 2009Date of Patent: August 31, 2010Inventors: David W. Old, Danny T. Dinh
-
Patent number: 7786221Abstract: Multi-armed, monofunctional, and hydrolytically stable polymers are described having the structure wherein Z is a moiety that can be activated for attachment to biologically active molecules such as proteins and wherein P and Q represent linkage fragments that join polymer arms polya and polyb, respectively, to central carbon atom, C, by hydrolytically stable linkages in the absence of aromatic rings in the linkage fragments. R typically is hydrogen or methyl, but can be a linkage fragment that includes another polymer arm. A specific example is an mPEG disubstituted lysine having the structure where mPEGa and mPEGb have the structure CH3O—(CH2CH2O)nCH2CH2— wherein n may be the same or different for polya- and polyb- and can be from 1 to about 1,150 to provide molecular weights of from about 100 to 100,000.Type: GrantFiled: September 18, 2008Date of Patent: August 31, 2010Assignee: Nektar TherapeuticsInventors: J. Milton Harris, Francesco Maria Veronese, Paola Caliceti, Oddone Schiavon
-
Patent number: 7786119Abstract: This invention is directed to drug conjugates of certain ion channel modulating compounds having the following formula: wherein A, X, R1, R2, R3, R4, R5, LB, L and DM are defined herein, including isolated enantiomeric and diastereomeric isomers thereof, and mixtures thereof. Pharmaceutical compositions and methods of use are also disclosed.Type: GrantFiled: March 31, 2005Date of Patent: August 31, 2010Assignee: Cardiome Pharma Corp.Inventors: Elizabeth L. S. Cheu, Lewis Siu Leung Choi, Doug Ta Hung Chou, Allen W. Davidoff, Alan M. Ezrin, Grace Jung, Bertrand M. C. Plouvier, Aregahegn S. Yifru
-
Publication number: 20100216734Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use nootropic agents, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.Type: ApplicationFiled: November 19, 2009Publication date: August 26, 2010Applicant: BrainCells, Inc.Inventors: Carrolee Barlow, Todd A. Carter, Andrew Morse, Kai Treuner, Kym I. Lorrain, Dana Gitnick, Jammieson C. Pires
-
Publication number: 20100215774Abstract: The present invention is related to the composition and methods of manufacture of orally-dissolvable, edible films as a vehicle for the non-invasive administration of nitroglycerin and/or other active drugs through the mucosal tissues of the oral cavity. The films include a water soluble film-forming polymer such as pullulan. Methods for producing the films are also disclosed.Type: ApplicationFiled: February 8, 2008Publication date: August 26, 2010Inventor: Todd Maibach
-
Publication number: 20100216689Abstract: Disclosed is a substance which has a low molecular weight, can be applied in a simpler manner, and has an immunopotentiating activity against cancer and/or a microorganism-mediated infectious disease. An EP4 agonist exhibits an immunopotentiating activity through the activation of a cytotoxic T cell, and is therefore useful for the prevention and/or treatment of cancer or a microorganism-mediated infection disease.Type: ApplicationFiled: May 7, 2008Publication date: August 26, 2010Applicants: ONO PHARMACEUTICAL CO., LTD.Inventors: Masahiro Takigawa, Naohiro Seo, Kenji Kabashima, Takayuki Maruyama, Toshiya Kanaji
-
Patent number: 7781482Abstract: A compound comprising or a pharmaceutically acceptable salt thereof, or a prodrug thereof is disclosed herein. Y, A, and B are as described herein. Methods, compositions, and medicaments related to these compounds are also disclosed.Type: GrantFiled: May 15, 2009Date of Patent: August 24, 2010Assignee: Allergan, Inc.Inventors: David W. Old, Danny T. Dinh
-
Patent number: 7781391Abstract: The present invention relates to amine functionalized lipophilic compounds and their use in personal care products, particularly those for colored hair.Type: GrantFiled: March 16, 2007Date of Patent: August 24, 2010Assignee: Croda, Inc.Inventors: Robert Comber, Abel G. Pereira
-
Publication number: 20100210706Abstract: The present invention relates to a compound represented by the following formula: or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a combination thereof, wherein R1, R2, and X are as defined herein. Compounds of the present invention are useful as progesterone receptor modulators.Type: ApplicationFiled: August 7, 2007Publication date: August 19, 2010Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: David G. Washburn, Scott Kevin Thompson, Marlys Hammond, James S. Frazee, Tram H. Hoang, Latisha C. Johnson
-
Publication number: 20100203084Abstract: The present invention provides a method for treating pain in a subject in need of treatment, by administering to the subject a non-opioid agent in combination with a selective excitatory-opioid-receptor inactivator, in amounts effective to treat pain in the subject. Also disclosed is a method for treating opioid-withdrawal effects in a subject in need of treatment, by the administration to the subject of a non-opioid agent in combination with a selective excitatory-opioid-receptor inactivator, in amounts effective to treat opioid-withdrawal effects in the subject. Finally, the present invention provides a pharmaceutical composition comprising a non-opioid agent and a selective excitatory-opioid-receptor inactivator, and a pharmaceutically-acceptable carrier.Type: ApplicationFiled: October 12, 2007Publication date: August 12, 2010Inventors: Stanley M. Crain, Ke-Fei Shen
-
Patent number: 7772406Abstract: Provided are: a process for production of a benzyloxypyrrolidine derivative in high yield and safety, and a process for production of a hydrochloride powder of a benzyloxypyrrolidine derivative in high yield and safety; the process for production of a benzyloxypyrrolidine derivative expressed by the general formula (2) [Chemical formula 2], in reacting a pyrrolidinol derivative represented by the general formula (1) [Chemical formula 1] with a benzyl halide derivative in the presence of an alkali metal hydroxide, wherein the reaction is carried out in either of the following conditions A or B; condition A: an aprotic polar solvent, and condition B: an aliphatic ether solvent containing a phase transfer catalyst:Type: GrantFiled: October 30, 2006Date of Patent: August 10, 2010Assignee: Toray Fine Chemicals Co., Ltd.Inventors: Masao Morimoto, Atsushi Yamakawa
-
Publication number: 20100197680Abstract: The present application relates to novel lactam-substituted dicarboxylic acid derivatives, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prevention of cardiovascular disorders.Type: ApplicationFiled: March 15, 2008Publication date: August 5, 2010Inventors: Michael Hahn, Eva-Maria Becker, Andreas Knorr, Dirk Schneider, Johannes-Peter Stasch, Karl-Heinz Schlemmer, Frank Wunder, Dieter Lang
-
Patent number: 7767830Abstract: Aminocyclohexyl ether compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses uses for the compounds and compositions, including the treatment of arrhythmia.Type: GrantFiled: March 23, 2007Date of Patent: August 3, 2010Assignee: Cardiome Pharma Corp.Inventors: Grace Jung, Bertrand M. C. Plouvier, Yuzhong Liu, Jeff Jiqun Zhu, Tao Sheng, Anthony G. M. Barrett, Lewis Siu Leung Choi, Doug Ta Hung Chou
-
Publication number: 20100190752Abstract: A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, whereby component (a) may be administered before or after component (b) and whereby components (a) or (b) are administered to the mammal either via the same or a different pathway of administration.Type: ApplicationFiled: January 26, 2010Publication date: July 29, 2010Applicant: Gruenenthal GmbHInventors: Klaus Schiene, Petra Bloms-Funke, Thomas Christoph
-
Publication number: 20100184764Abstract: The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia.Type: ApplicationFiled: March 19, 2010Publication date: July 22, 2010Applicant: ELI LILLY AND COMPANYInventors: Thomas Daniel AICHER, Mark Joseph CHICARELLI, Ronald Jay HINKLIN, Hongqi TIAN, Owen Brendan WALLACE, John Gordon ALLEN, Zhaogen CHEN, Thomas Edward MABRY, Jefferson Ray MCCOWAN, Nancy June SNYDER, Leonard Larry WINNEROSKI, JR.
-
Publication number: 20100184727Abstract: A muscarinic receptor antagonist is useful for the treatment or prevention of a condition associated with excess sebum production or excretion.Type: ApplicationFiled: June 7, 2007Publication date: July 22, 2010Applicant: SUMMIT (CAMBRIDGE) LIMITEDInventors: Alan Geoffrey Roach, Paul Goldsmith
-
Publication number: 20100179211Abstract: The present invention relates to the use of compounds which increase extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically to the use of 3-disubstituted phenyl-1-pyrrolidinols for the treatment of central nervous system disorders.Type: ApplicationFiled: June 4, 2008Publication date: July 15, 2010Applicant: NSAB, FILIAL AF NEUROSEARCH SWEDEN ABInventors: Clas Sonesson, Lars Swanson, Fredrik Pettersson, Nicholas Waters, Susanna Waters
-
Patent number: 7754758Abstract: Compounds of formula I in free or salt form, wherein T, X, Y, U, R1, R2, m, n and p have the meanings as indicated in the specification, are useful for treating conditions mediated by CCR3. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.Type: GrantFiled: January 28, 2005Date of Patent: July 13, 2010Assignee: Novartis AGInventors: Gurdip Bhalay, Andrew Dunstan, Angela Glen, Trevor John Howe, Clive McCarthy
-
Publication number: 20100173880Abstract: Alkaloid aminoester compounds which act as muscarinic receptor antagonists are useful for the prevention and/or treatment of a broncho-obstructive or inflammatory diseases.Type: ApplicationFiled: December 22, 2009Publication date: July 8, 2010Applicant: Chiesi Farmaceutici S.p.A.Inventors: Antonio Caligiuri, Mauro Riccaboni, Gabriele Amari
-
Publication number: 20100172979Abstract: Disclosed herein are controlled-release formulations containing a core comprising a core active agent (e.g., levetiracetam) and a wax excipient, where the core is substantially coated with an extended-release coating.Type: ApplicationFiled: December 18, 2009Publication date: July 8, 2010Inventors: Zhongshui Yu, Kristin Arnold, Siva Rama K. Nutalapati
-
Publication number: 20100166889Abstract: The invention provides methods of treating depressive disorders, in particular major depression but other depressive orders also, with prodrug stimulants or analogs including amphetamine prodrugs, methylphenidate prodrugs, and methylphenidate analogs, Such methods of treatment may utilize the prodrug stimulant or analog as monotherapy or, more commonly, as an adjunct to antidepressant medication treatment to augment their effect. The invention includes combination methods of treatment in which an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is administered to an individual in need with one or more other active agents, either in separate forms or as a single pharmaceutical formulation. Packaged pharmaceutical compositions containing an amphetamine or methylphenidate prodrug, instructions for using the prodrug to treat certain disorders, and optionally one or more other active agents are provided by the invention.Type: ApplicationFiled: December 23, 2009Publication date: July 1, 2010Applicant: LCS GROUP, LLCInventor: Louis Sanfilippo
-
Publication number: 20100168189Abstract: Therapeutic compounds, compositions, methods, and medicaments related thereto are disclosed herein.Type: ApplicationFiled: February 8, 2008Publication date: July 1, 2010Inventors: David W. Old, Wha Bin Im, Vinh X. Ngo
-
Publication number: 20100159034Abstract: The present invention relates to new pyrrolidinone inhibitors of PDE-4 activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: December 15, 2009Publication date: June 24, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Publication number: 20100159009Abstract: Disclosed herein are extended-release levetiracetam formulations having a matrix comprising levetiracetam and a hydrophobic excipient or an acrylic polymer excipient.Type: ApplicationFiled: December 18, 2009Publication date: June 24, 2010Inventors: Zhongshui Yu, Kristin Arnold, Siva Rama K. Nutalapati
-
Publication number: 20100158965Abstract: There is disclosed a product for attracting and destroying insects which comprises an active-substance-comprising bait layer (1) together with a bait substance and an insecticide. The active-substance-comprising bait layer (1) furthermore comprises a superdisintegrant whose effect is that, upon the use of the product in an environment with high atmospheric humidity, the active-substance-comprising bait layer (1) does not run.Type: ApplicationFiled: December 18, 2009Publication date: June 24, 2010Inventors: Else Beitzel, Hermann-Josef Jaeckels, Malgorzata Kloczko, Birgit Kocherscheidt, Thomas Böcker
-
Patent number: 7741351Abstract: This case discloses compounds of formula (I) wherein R1 is C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, amino, monoC1-4alkylamino or diC1-4alkylamino; R2 and R3, which may be the same or different, are hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano or amino; each R4, which may be the same or different, is C1-6alkyl, halogen, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, nitro or amino; p is 0, 1 or 2; each R5, which may be the same or different, is C1-6alkyl, halogen, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, nitro or amino; q is 0, 1 or 2; R6 is —NR6aSO2R6b, —NR6aC(?O)R6b, —NR6a(C?O)N(R6c)2, —(C?O)R6d, —CH2NR6aSO2R6b, —CH2NR6aC(?O)R6b, CH2NR6a(C?O)N(R6c)2 or —CH2(C?O)R6d; where R6a and each R6c, which may be the same or different, is hydrogen or C1-6alkyl; R6b and R6d are C1-6alkyl or haloC1-6alkyl; or R6a and R6b, or R6a and R6c, together with the interconnecting atoms, may form a 5- or 6-membered ring; n is 1 or 2; and R7 and R8, which may be the same or different, areType: GrantFiled: August 5, 2005Date of Patent: June 22, 2010Assignee: Glaxo Group LimitedInventors: Kevin Michael Thewlis, Simon Edward Ward
-
Publication number: 20100152138Abstract: Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is R is —C(O)—N(R27)(R28) or and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a ?-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.Type: ApplicationFiled: December 18, 2009Publication date: June 17, 2010Inventors: Jared N. Cumming, Ulrich Iserloh, Andrew Stamford, Corey Strickland, Johannes H. Voigt, Yusheng Wu, Ying Huang, Yan Xia, Samuel Chackalamannil, Tao Guo, Douglas W. Hobbs, Thuy X.H. Le, Jeffrey F. Lowrie, Kurt W. Saionz, Suresh D. Babu
-
Publication number: 20100151018Abstract: A subject of the present invention is a novel formulation of levetiracetam making it possible to obtain a solid pharmaceutical composition, particularly intended for oral administration, for the sustained release of levetiracetam. A subject of the invention is also a process for the preparation of such a pharmaceutical composition.Type: ApplicationFiled: February 5, 2008Publication date: June 17, 2010Applicant: RD- PharmagalInventors: Hervé Brochart, Estelle Foucher
-
Publication number: 20100152236Abstract: A compound represented by the formula (I) wherein ring A is a 5- to 8-membered ring optionally having further substituent(s) other than R6, R7 and R8, R1 is an electron-withdrawing group, R2, R3, R4 and R5 are each independently a hydrogen atom, a halogen atom, a group bonded via a carbon atom, a group bonded via a nitrogen atom, a group bonded via an oxygen atom or a group bonded via a sulfur atom, R6 is a halogen atom, a group bonded via a carbon atom, a group bonded via a nitrogen atom, a group bonded via an oxygen atom or a group bonded via a sulfur atom, R7 is a cyano group, a nitro group, an acyl group optionally having substituent(s), an optionally esterified or amidated carboxyl group or a hydrocarbon group optionally having substituent(s), or R6 and R7 optionally form, together with the carbon atom bonded thereto, a ring optionally having substituent(s), and R8 is a hydrogen atom, a halogen atom, a group bonded via a carbon atom, a group bonded via a nitrogen atom, a group bonded via an oxygType: ApplicationFiled: August 1, 2006Publication date: June 17, 2010Applicant: Takeda Pharmaceutical Company LimitedInventors: Satoshi Yamamoto, Atsushi Hasuoka
-
Publication number: 20100152276Abstract: This invention is directed to deuterated aminocyclohexyl ether compounds and processes for preparing same and methods of using same.Type: ApplicationFiled: February 26, 2010Publication date: June 17, 2010Applicant: Cardiome Pharma Corp.Inventors: Doug Ta Hung Chou, Bertrand M. C. Plouvier, Peter Pang, James Gee Ken Yee, Jeffery Jerome Wheeler, Aregahegn S. Yifru, Allen W. Davidoff
-
Patent number: 7732481Abstract: Novel compounds of the formula (I), in which R, R1, R2, R3, X, X? and Y have the meaning indicated in Patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors.Type: GrantFiled: November 26, 2004Date of Patent: June 8, 2010Assignee: Merck Patent Gesellschaft mit beschrankter HaftungInventors: Werner Mederski, Christos Tsaklakidis, Dieter Dorsch, Bertram Cezanne, Johannes Gleitz
-
Publication number: 20100125096Abstract: The present invention provides a method of treatment, prevention and/or delay of progression of neuropathic pain by a specific dosing regime of acetam derivatives.Type: ApplicationFiled: September 24, 2009Publication date: May 20, 2010Applicant: NEUROTUNE AGInventors: Carlo Farina, Carla Ghelardini, Ruggero Fariello
-
Patent number: 7718693Abstract: The present invention relates to novel oxo-prolinamide derivatives of formula (I) which modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of disorders mediated by the P2X7 receptor, for example pain, inflammation and neurodegeneration.Type: GrantFiled: July 3, 2007Date of Patent: May 18, 2010Assignee: Glaxo Group LimitedInventor: Daryl Simon Walter
-
Publication number: 20100120890Abstract: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, early afterdepolarizations and prolongation of QT interval may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.Type: ApplicationFiled: January 19, 2010Publication date: May 13, 2010Applicant: CARDIOME PHARMA CORP.Inventors: David Fedida, Gregory N. Beatch, Alan M. Ezrin, Peter M. R. Orth, Christian Hesketh
-
Patent number: 7713979Abstract: The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia.Type: GrantFiled: October 26, 2005Date of Patent: May 11, 2010Assignee: Eli Lilly and CompanyInventors: Thomas Daniel Aicher, Mark Joseph Chicarelli, Ronald Jay Hinklin, Hongqi Tian, Owen Brendan Wallace, John Gordon Allen, Zhaogen Chen, Thomas Edward Mabry, Jefferson Ray McCowan, Nancy June Snyder, Leonard Larry Winneroski, Jr.
-
Patent number: 7713959Abstract: Disclosed are pharmaceutical compositions comprising mirtazapine and an anticonvulsant drug. Also disclosed are methods of preventing weight gain associated with the administration of mirtazapine comprising identifying a patient to whom mirtazapine is to be administered and administering to said patient a pharmaceutical composition comprising mirtazapine and an anticonvulsant drug. Further disclosed are methods of increasing the efficacy of mirtazapine comprising identifying a patient to whom mirtazapine is to be administered and administering to said patient a pharmaceutical composition comprising mirtazapine and an anticonvulsant drug.Type: GrantFiled: August 31, 2005Date of Patent: May 11, 2010Assignee: Duke UniversityInventors: K. Ranga R. Krishnan, Kishore M. Gadde
-
Publication number: 20100113388Abstract: An 8-azaprostaglandin represented by formula (I) (wherein all symbols have the same meanings as described in the specification), a pharmaceutically acceptable salt thereof or a cyclodextrin clathrate thereof.Type: ApplicationFiled: January 7, 2010Publication date: May 6, 2010Applicant: Ono Pharmaceutical Co., Ltd.Inventors: Kousuke Tani, Kaoru Kobayashi, Toru Maruyama, Tohru Kambe, Mikio Ogawa, Tsutomu Shiroya
-
Publication number: 20100113460Abstract: Disclosed are compounds having the ability to inhibit cytochrome P450 2A6, 2A13, and/or 2B6 and tobacco products comprising them. Also disclosed are pharmaceutical compositions comprising them.Type: ApplicationFiled: March 20, 2008Publication date: May 6, 2010Applicant: Givaudan SAInventors: Boris Schilling, Wolf D. Woggon, Antoinette Chougnet, Thierry Granier, Georg Frater, Andreas Hanhart
-
Patent number: 7705037Abstract: The present invention relates to compounds of formula (I). These compounds are a novel type of peptide deformylase (PDF) inhibitors, and are therefore of great interest especially as new antibiotics.Type: GrantFiled: June 6, 2006Date of Patent: April 27, 2010Assignee: Novartis AGInventor: Michael Thormann
-
Patent number: 7705036Abstract: This invention is directed to deuterated aminocyclohexyl ether compounds and processes for preparing same and methods of using same.Type: GrantFiled: October 13, 2006Date of Patent: April 27, 2010Assignee: Cardiome Pharma Corp.Inventors: Doug Ta Hung Chou, Bertrand M.C. Plouvier, Peter Pang, James Gee Ken Yee, Jeffrey Jerome Wheeler, Aregahegn S. Yifru, Allen W. Davidoff
-
Patent number: 7700587Abstract: Haloperidol analogs that conforms to the structural formulae: wherein: R is H, or —(CH2)n—OH, n is an integer from 0 to 2, and A is a heterocyclic bridging group, consisting essentially of carbon and at least one nitrogen atom, which effectively maintains the distance between the moieties connected thereby such that the compound (1) is incapable of metabolizing to BCPP+ like species, (2) has an affinity for the D2 receptor subtype of 15<D2<250 and (3) functions as a dopamine receptor antagonist, or the structural formulae: wherein: R1 is H, or —(CH2)n—OH, n is an integer from 0 to 2, B is an aza- or diaza-bicyclo group, which effectively maintains the distance between the moieties connected thereby such that the compound is incapable of metabolizing to BCPP+ like species; and Z is —CH— or N; and pharmaceutically acceptable salts, esters, derivatives, metal complexes, conjugates and prodrugs thereof.Type: GrantFiled: September 7, 2004Date of Patent: April 20, 2010Assignee: Florida A&M UniversityInventors: Seth Y. Ablordeppey, Donald M. N. Sikazwe